Product image of Juzina (Sitagliptin) supplied by GNH India

Juzina

Active Ingredient:
Sitagliptin
Origin:
EU

Juzina (Sitagliptin)

Sitagliptin, the active ingredient in Juzina, is a DPP‑4 inhibitor presented as a tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to lower elevated blood glucose levels when used together with diet and exercise. It is available in standard tablet strengths and is manufactured under strict GMP conditions.

GNH India supplies Juzina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing consistent quality and regulatory compliance for global distribution across multiple regions and therapeutic markets.

Manufacturer / TM Owner

Gedeon Richter Plc.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Sitagliptin is used in the management of type 2 diabetes mellitus, acting on the incretin pathway to improve glycemic control.

  • Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels as part of a comprehensive treatment plan.
  • Type 2 diabetes mellitus (combination therapy with metformin): provides additional HbA1c reduction when added to metformin.
  • Type 2 diabetes mellitus (adjunct to diet and exercise): assists patients in achieving target glycemic goals alongside lifestyle modifications.

How It Works

  • Sitagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which degrades the incretin hormones GLP‑1 and GIP. By blocking DPP‑4, endogenous GLP‑1 and GIP levels rise, leading to glucose‑dependent stimulation of insulin secretion and suppression of glucagon release, thereby reducing both fasting and post‑prandial blood glucose concentrations without causing hypoglycaemia when used alone.

Side Effects

Sitagliptin may be associated with a range of adverse reactions, most of which are mild and transient.

Common Side Effects

  • Nasopharyngitis: mild inflammation of the nose and throat.
  • Headache: transient cranial pain.
  • Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain indicating possible pancreatic inflammation.
  • Severe allergic reactions: rash, angioedema or anaphylaxis.
  • Joint pain: unexplained arthralgia.

Precautions & Warnings

When prescribing sitagliptin, clinicians should consider several safety aspects to minimise risk.

  • Renal impairment: dose adjustment or avoidance is recommended in patients with reduced kidney function.
  • Hepatic impairment: use with caution in patients with liver disease and monitor liver enzymes.
  • Concomitant sulfonylureas or insulin: increased risk of hypoglycaemia; monitor blood glucose closely.
  • Elderly patients: may be more susceptible to adverse effects; start at the lowest effective dose.
  • Cardiovascular risk: assess for history of heart failure, although no direct contraindication.
  • Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Avoid Interactions

Sitagliptin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Co‑administration with strong DPP‑4 inhibitors (e.g., saxagliptin): may increase risk of adverse effects; avoid simultaneous use.
  • Combined use with insulin or sulfonylureas: can cause severe hypoglycaemia; dose adjustments required.

Moderate Interactions (Monitor Closely)

  • Rifampin: induces metabolism and may reduce sitagliptin plasma levels, decreasing effectiveness.
  • Diuretics (e.g., thiazides): may enhance hypoglycaemic effect; monitor glucose.
  • ACE inhibitors or ARBs: potential additive effect on blood pressure; observe patient response.

Frequently Asked Questions

Juzina contains sitagliptin, which is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus. It is used as part of a comprehensive treatment plan that includes diet, exercise and, when appropriate, other antidiabetic medications.

Sitagliptin works by selectively inhibiting the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition raises levels of the incretin hormones GLP‑1 and GIP, which increase insulin secretion and reduce glucagon release in a glucose‑dependent manner, thereby lowering blood sugar.

The dose of Juzina is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of sitagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Juzina, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Juzina (sitagliptin) belongs to the DPP‑4 inhibitor class, which differs from metformin (biguanide) or sulfonylureas in its mechanism. It offers glucose‑dependent insulin secretion with a low risk of hypoglycaemia when used alone, making it a useful option for patients who cannot tolerate metformin or need additional control beyond it.

Store Juzina tablets at ambient temperature, below 25 °C, in the original packaging. Keep them away from moisture, direct sunlight and heat sources to maintain product stability throughout its shelf life.

Juzina is taken orally as a tablet, usually once daily. It can be swallowed with or without food, and patients should use a full glass of water to ensure proper ingestion.

The most serious adverse events reported with sitagliptin include pancreatitis, severe allergic reactions such as anaphylaxis, and unexplained joint pain. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling or severe joint discomfort.

Juzina should be avoided in individuals with known hypersensitivity to sitagliptin or any component of the tablet. It is also contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) unless dose‑adjusted under specialist supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT